Published in Cancer Res on February 03, 2012
ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis. Cell (2015) 2.63
Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. Immunity (2014) 1.69
Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity. Cell Rep (2012) 1.46
Role of miR-155 in the regulation of lymphocyte immune function and disease. Immunology (2014) 1.23
MicroRNA-mediated control of macrophages and its implications for cancer. Trends Immunol (2013) 1.22
Tumor-altered dendritic cell function: implications for anti-tumor immunity. Front Immunol (2013) 1.17
MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment. Oncogene (2015) 1.16
The role of microRNAs in ovarian cancer. Biomed Res Int (2014) 1.15
MicroRNA regulons in tumor microenvironment. Oncogene (2014) 1.08
Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism. Cancer Res (2014) 1.06
Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease. Mol Immunol (2013) 1.02
OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer. Cancer Res (2016) 1.02
Inactivation of tumor-specific CD8⁺ CTLs by tumor-infiltrating tolerogenic dendritic cells. Immunol Cell Biol (2013) 0.92
The role of myeloid cells in cancer therapies. Nat Rev Cancer (2016) 0.92
BRCA1 and microRNAs: emerging networks and potential therapeutic targets. Mol Cells (2012) 0.90
Targeting microRNAs as key modulators of tumor immune response. J Exp Clin Cancer Res (2016) 0.89
Tumor-infiltrating dendritic cells in cancer pathogenesis. J Immunol (2015) 0.87
Tissue slide-based microRNA characterization of tumors: how detailed could diagnosis become for cancer medicine? Expert Rev Mol Diagn (2014) 0.87
MicroRNA Targeting to Modulate Tumor Microenvironment. Front Oncol (2016) 0.86
Cancer-Associated Myeloid Regulatory Cells. Front Immunol (2016) 0.85
Perspectives on reprograming cancer-associated dendritic cells for anti-tumor therapies. Front Oncol (2014) 0.84
Anti-tumor immunity: myeloid leukocytes control the immune landscape. Cell Immunol (2012) 0.84
Satb1 Overexpression Drives Tumor-Promoting Activities in Cancer-Associated Dendritic Cells. Cell Rep (2016) 0.83
Cell transfer therapy for cancer: past, present, and future. J Immunol Res (2014) 0.83
The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape. Front Immunol (2013) 0.83
The Tumor Macroenvironment: Cancer-Promoting Networks Beyond Tumor Beds. Adv Cancer Res (2015) 0.83
Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy. Expert Rev Obstet Gynecol (2012) 0.82
Good things come in small packages: Therapeutic anti-tumor immunity induced by microRNA nanoparticles. Oncoimmunology (2012) 0.81
A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression. Mol Syst Biol (2015) 0.80
miR-155 Controls Lymphoproliferation in LAT Mutant Mice by Restraining T-Cell Apoptosis via SHIP-1/mTOR and PAK1/FOXO3/BIM Pathways. PLoS One (2015) 0.80
Antigen specific immune response in Chlamydia muridarum genital infection is dependent on murine microRNAs-155 and -182. Oncotarget (2016) 0.79
Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer. Front Immunol (2013) 0.78
Stimulating antitumor immunity with nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2014) 0.78
Double agents in the war on cancer: leukocytes govern ovarian cancer progression. Oncotarget (2012) 0.78
Dysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor Immunity. J Clin Med (2016) 0.77
T Lymphocyte Inhibition by Tumor-Infiltrating Dendritic Cells Involves Ectonucleotidase CD39 but Not Arginase-1. Biomed Res Int (2015) 0.77
IL12B expression is sustained by a heterogenous population of myeloid lineages during tuberculosis. Tuberculosis (Edinb) (2013) 0.77
Reprogramming immune responses via microRNA modulation. Microrna Diagn Ther (2013) 0.77
MicroRNAs Involved in Anti-Tumour Immunity. Int J Mol Sci (2013) 0.77
Inhibition of vascular endothelial growth factor by small interfering RNA upregulates differentiation, maturation and function of dendritic cells. Exp Ther Med (2014) 0.76
Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets. Int J Mol Sci (2016) 0.76
Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics. Crit Rev Oncog (2014) 0.76
Tumorigenic and Immunosuppressive Effects of Endoplasmic Reticulum Stress in Cancer. Cell (2017) 0.75
A Circulating microRNA Signature Predicts Age-Based Development of Lymphoma. PLoS One (2017) 0.75
Rewiring macrophages for anti-tumour immunity. Nat Cell Biol (2016) 0.75
miRNA nanotherapeutics for cancer. Drug Discov Today (2016) 0.75
State-of-the-art of regulatory dendritic cells in cancer. Pharmacol Ther (2016) 0.75
Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target. Clin Cancer Res (2016) 0.75
Expression of natural killer cell regulatory microRNA by uveal melanoma cancer stem cells. Clin Exp Metastasis (2016) 0.75
Endogenous and tumour-derived microRNAs regulate cross-presentation in dendritic cells and consequently cytotoxic T cell function. Cytotechnology (2016) 0.75
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
The functions of animal microRNAs. Nature (2004) 64.85
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Requirement of bic/microRNA-155 for normal immune function. Science (2007) 16.24
Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature (2009) 14.07
Regulation of the germinal center response by microRNA-155. Science (2007) 12.25
Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol (2009) 11.50
MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A (2007) 11.42
miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell (2007) 9.08
Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol (2010) 7.75
MicroRNA control in the immune system: basic principles. Cell (2009) 7.16
Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov (2010) 6.07
Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med (2008) 5.97
SATB1 packages densely looped, transcriptionally active chromatin for coordinated expression of cytokine genes. Nat Genet (2006) 5.62
Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol (2004) 5.40
Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity (2009) 5.10
Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis (2000) 4.06
Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity (2010) 3.88
Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med (2004) 3.55
Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res (2005) 2.83
Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest (2009) 2.06
Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol (2004) 2.05
Vascular leukocytes contribute to tumor vascularization. Blood (2004) 2.03
Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res (2008) 1.92
Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J Clin Invest (2010) 1.91
MicroRNA-155 modulates the pathogen binding ability of dendritic cells (DCs) by down-regulation of DC-specific intercellular adhesion molecule-3 grabbing non-integrin (DC-SIGN). J Biol Chem (2009) 1.74
In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res (2009) 1.67
MicroRNA-155 regulates inflammatory cytokine production in tumor-associated macrophages via targeting C/EBPbeta. Cell Mol Immunol (2009) 1.66
Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clin Cancer Res (2010) 1.44
Thermodynamic stability of small hairpin RNAs highly influences the loading process of different mammalian Argonautes. Proc Natl Acad Sci U S A (2011) 1.28
CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells. Oncotarget (2010) 1.20
CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells. J Immunol (2010) 1.15
CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion. Cancer Res (2009) 1.14
Transfusion-related immunomodulation due to peripheral blood dendritic cells expressing the CD200 tolerance signaling molecule and alloantigen. Transfusion (2008) 0.96
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
MicroRNAs and the advent of vertebrate morphological complexity. Proc Natl Acad Sci U S A (2008) 3.00
MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res (2011) 2.95
MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest (2010) 2.87
Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med (2012) 2.85
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol (2009) 2.66
Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res (2004) 2.48
Pancreatic cancer and precursor pancreatic intraepithelial neoplasia lesions are devoid of primary cilia. Cancer Res (2009) 2.43
Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res (2009) 2.19
The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia. Proc Natl Acad Sci U S A (2007) 2.18
Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest (2009) 2.06
Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras. Biochem Biophys Res Commun (2009) 2.04
Influenza virus infection decreases tracheal mucociliary velocity and clearance of Streptococcus pneumoniae. Am J Respir Cell Mol Biol (2009) 1.95
Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res (2008) 1.92
Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem (2008) 1.87
Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol Cancer Ther (2006) 1.71
In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res (2009) 1.67
Retracted Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer. J Cell Physiol (2012) 1.67
Targeted disruption of the type 1 selenodeiodinase gene (Dio1) results in marked changes in thyroid hormone economy in mice. Endocrinology (2005) 1.53
Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care (2011) 1.52
Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells. J Cell Biol (2005) 1.51
Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clin Cancer Res (2010) 1.44
Dual positive and negative regulation of wingless signaling by adenomatous polyposis coli. Science (2008) 1.44
Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. J Immunol (2004) 1.43
Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. J Clin Invest (2008) 1.43
PILAR is a novel modulator of human T-cell expansion. Blood (2008) 1.33
Neuropilin-1 interacts with integrin beta1 and modulates pancreatic cancer cell growth, survival and invasion. Cancer Biol Ther (2007) 1.28
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res (2007) 1.27
Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1. Cancer Res (2007) 1.26
Loss of beta-catenin expression in metastatic gastric cancer. J Clin Oncol (2003) 1.22
CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells. Oncotarget (2010) 1.20
Adhesion molecules in human pancreatic cancer. J Surg Oncol (2002) 1.19
Reverse transcription-PCR analysis of laser-captured cells points to potential paracrine and autocrine actions of neurotrophins in pancreatic cancer. Clin Cancer Res (2003) 1.19
Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression. Cancer Res (2007) 1.18
14-3-3sigma Modulates pancreatic cancer cell survival and invasiveness. Clin Cancer Res (2008) 1.17
Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge. J Immunol (2012) 1.16
Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop. Pancreas (2013) 1.15
CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells. J Immunol (2010) 1.15
Advances, challenges, and limitations in serum-proteome-based cancer diagnosis. J Proteome Res (2006) 1.14
CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion. Cancer Res (2009) 1.14
The diaphragms of fenestrated endothelia: gatekeepers of vascular permeability and blood composition. Dev Cell (2012) 1.13
Nestin is a novel target for suppressing pancreatic cancer cell migration, invasion and metastasis. Cancer Biol Ther (2011) 1.13
FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth. Int J Cancer (2006) 1.12
Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. Mol Cancer Ther (2002) 1.11
Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-κB signaling pathways. PLoS One (2011) 1.11
Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells. Gastroenterology (2003) 1.11
Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med (2009) 1.10
Enhanced expression of keratinocyte growth factor and its receptor correlates with venous invasion in pancreatic cancer. Am J Pathol (2007) 1.10
Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther (2012) 1.10
Immunotherapy for gynaecological malignancies. Expert Opin Biol Ther (2005) 1.10
Nestin expression correlates with nerve and retroperitoneal tissue invasion in pancreatic cancer. Hum Pathol (2008) 1.10
Pancreatic cancer-associated retinoblastoma 1 dysfunction enables TGF-β to promote proliferation. J Clin Invest (2013) 1.10
UBE1L causes lung cancer growth suppression by targeting cyclin D1. Mol Cancer Ther (2008) 1.09
Kinase signaling pathways as targets for intervention in pancreatic cancer. Cancer Biol Ther (2010) 1.09
Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. Cell Cycle (2013) 1.08
Induction and expression of betaig-h3 in pancreatic cancer cells. Biochim Biophys Acta (2002) 1.08
Nerve growth factor and enhancement of proliferation, invasion, and tumorigenicity of pancreatic cancer cells. Mol Carcinog (2002) 1.07
Acute pancreatitis accelerates initiation and progression to pancreatic cancer in mice expressing oncogenic Kras in the nestin cell lineage. PLoS One (2011) 1.07
Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment. Cancer Res (2013) 1.06
Vascular leukocytes: a population with angiogenic and immunossuppressive properties highly represented in ovarian cancer. Adv Exp Med Biol (2007) 1.06
Enhanced expression of 14-3-3sigma in pancreatic cancer and its role in cell cycle regulation and apoptosis. Carcinogenesis (2004) 1.06
Deletion of Rb accelerates pancreatic carcinogenesis by oncogenic Kras and impairs senescence in premalignant lesions. Gastroenterology (2011) 1.05
Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma. Oncogene (2004) 1.05
VISTA is an immune checkpoint molecule for human T cells. Cancer Res (2014) 1.03
Thioredoxin is downstream of Smad7 in a pathway that promotes growth and suppresses cisplatin-induced apoptosis in pancreatic cancer. Cancer Res (2004) 1.03
A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells. Cancer Biol Ther (2011) 1.03
Aberrant expression of neuropilin-1 and -2 in human pancreatic cancer cells. Clin Cancer Res (2004) 1.02
Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. Cell Cycle (2010) 1.02
Defined localization of nestin-expressing cells in L-arginine-induced acute pancreatitis. Pancreas (2006) 1.01
Targeting angiogenesis in pancreatic cancer: rationale and pitfalls. Langenbecks Arch Surg (2008) 1.01
Interleukin-13 exerts autocrine growth-promoting effects on human pancreatic cancer, and its expression correlates with a propensity for lymph node metastases. Int J Colorectal Dis (2008) 0.99
Signaling pathways in pancreatic cancer. Crit Rev Eukaryot Gene Expr (2011) 0.99
Adenomatous polyposis coli is present near the minimal level required for accurate graded responses to the Wingless morphogen. Development (2008) 0.99
Microarray analysis of cytoplasmic versus whole cell RNA reveals a considerable number of missed and false positive mRNAs. RNA (2009) 0.98
Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. Int J Oncol (2004) 0.98
Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway. Cancer Lett (2008) 0.96
Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Invest (2003) 0.96
DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistance. PLoS One (2011) 0.96
Involvement of microRNAs in lung cancer biology and therapy. Transl Res (2011) 0.96
Enhanced expression of fibroblast growth factor receptor 2 IIIc promotes human pancreatic cancer cell proliferation. Am J Pathol (2012) 0.95
Nanomolecular targeting of dendritic cells for ovarian cancer therapy. Future Oncol (2009) 0.94